Advances in the Study of Inhaled Formulations for the Treatment of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a serious disease with reduced systemic circulation and low bioavailability associated with conventional and dosed therapy, which inhaled drugs can avoid. A mean pulmonary artery pressure (mPAP) of ≥25 mmHg (1 mmHg=0.133 kPa) at rest or ≥30 mmHg during exerci...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Applied Bionics and Biomechanics |
| Online Access: | http://dx.doi.org/10.1155/2022/6495645 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|